37-3
37th Parliament,
3rd Session
(February 2, 2004 - May 23, 2004)
Select a different session
Witnesses
Results per page:
10
Organization Activate to sort column ascending Activate to sort column descending | Name / Title Activate to sort column ascending Activate to sort column descending | Study/Bill Activate to sort column ascending Activate to sort column descending | Date/Time Activate to sort column ascending | Links/Notes |
---|---|---|---|---|
Foreign Affairs and International Trade Canada | Christopher Armstrong, Senior Advisor, HIV/AIDS, Human Rights, Humanitarian Affairs and International Women's Equality Division | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
Industry Canada | Susan Bincoletto, Acting Director General, Marketplace Framework Policy Branch | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
Canadian International Development Agency | Sandra Black, Director, Social Development Policies, Policy Branch | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
Canada's Research-Based Pharmaceutical Companies | Adrienne Blanchard, Legal Counsel, Gowling, Lafleur and Henderson | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
Industry Canada | Doug Clark, Senior Project Leader, Patent Policy Directorate | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
Industry Canada | Éric Dagenais, Director, Patent Policy Directorate | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
The Honourable Bill Graham, P.C., M.P., Minister of Foreign Affairs | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
|
Canadian Generic Pharmaceutical Association | Jim Keon, President | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
Health Canada | David K. Lee, Directorate, Office of Patented Medicines and Liaison, Therapeutic Products Directorate, Health Products and Food Branch | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|
Canada's Research-Based Pharmaceutical Companies | Jean-François Leprince, President, Aventis Pharmaceutical, Chair, Rx&D Intellectual Property Committee | Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act | May 12, 2004 |
|